Charles River Laboratories International, Inc. (CRL) Financials
Key financial figures for Charles River Laboratories International, Inc. (Q3 2026).
Charles River grew organically 4.7% in Q3 2026 and raised 2026 non-GAAP EPS guidance to $11.35 to $11.55 from $11.15 to $11.45, while reported revenue fell 2.2% to $982.7 million after the May divestitures. Revenue was $982.7 million, down 2.2% from $1,004.9 million a year earlier on the May 2026 divestitures; organic revenue grew 4.7%, which the company said outperformed its prior outlook and marked a second straight quarter of organic growth. Non-GAAP EPS was $3.09, up 27.2% from $2.43, on a non-GAAP operating margin of 23.0% (up 330 basis points from 19.7%) and a lower tax rate. GAAP EPS was $6.86 versus $1.10, including a $5.06 per share benefit from the reversal of acquired tax reserves. On the outlook: 2026 organic revenue growth of at least +1.5% (prior 0.0% to +1.0%); reported revenue growth of (2.0)% to (1.5)% (prior (3.5)% to (2.5)%); non-GAAP EPS of $11.35 to $11.55 (prior $11.15 to $11.45); GAAP EPS of $8.15 to $8.35 (prior $3.05 to $3.35). Figures are for Q3 2026, as Charles River Laboratories reported them.
- Revenue
- $983M
- Net Income
- $333M
- EPS
- $6.97
- Total Assets
- $7.5B
- Operating Cash Flow
- $254M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $983M | $333M | $6.86 | 20.62% | $207M |
| Q2 FY2026 | $1.0B | -$1M | -$0.03 | 11.94% | $149M |
| Q1 FY2026 | $996M | -$15M | -$0.30 | 12.04% | -$15M |
| Q4 FY2025 | $994M | -$277M | -$5.62 | 12.09% | $59M |
| Q3 FY2025 | $1.0B | $54M | $1.10 | 13.32% | $178M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4.0B | -$144M | -$2.91 | 12.65% | $518M |
| FY2024 | $4.0B | $10M | $0.20 | 5.61% | $502M |
| FY2023 | $4.1B | $475M | $9.22 | 14.95% | $365M |
Frequently asked questions
What was Charles River Laboratories's revenue last quarter?
Charles River Laboratories reported revenue of $982.7 million for Q3 FY2026, down 2.2% from the same period a year earlier.
Is Charles River Laboratories profitable?
Yes. Charles River Laboratories reported net income of $333.1 million for Q3 FY2026, a net margin of 33.89% on revenue.
How has Charles River Laboratories's margin trended?
Operating margin was 20.62% in Q3 FY2026, compared with 13.32% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Charles River Laboratories generate?
Charles River Laboratories generated free cash flow of $207.3 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Charles River Laboratories International, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.